Use of the Selective Oral Neuraminidase Inhibitor Oseltamivir to Prevent Influenza
Frederick G. Hayden, M.D., Robert L. Atmar, M.D., Margo Schilling, M.D., Casey Johnson, D.O., Donald Poretz, M.D., David Paar, M.D., Les Huson, Ph.D., Penelope Ward, M.D., Roger G. Mills, M.D., for The Oseltamivir Study Group
Background Safe and effective antiviral agents are needed toprevent infection with influenza A and B viruses. Oseltamivir(GS4104), which can be administered orally, is the prodrug ofGS4071, a potent and selective inhibitor of influenzavirus neuraminidases.We studied the use of oseltamivir for long-term prophylaxisagainst influenza in two placebo-controlled, double-blind trialsat different U.S. sites during the winter of 1997–1998.
Methods We randomly assigned 1559 healthy, nonimmunized adults18 to 65 years old to receive either oral oseltamivir (75 mggiven once or twice daily, for a total daily dose of 75 or 150mg) or placebo for six weeks during a peak period of local influenzavirusactivity. The primary end point with respect to efficacy waslaboratory-confirmed influenza-like illness (defined as a temperatureof at least 37.2°C accompanied by at least one respiratoryand at least one systemic symptom).
Results In the two studies combined, the risk of influenza amongsubjects assigned to either once-daily or twice-daily oseltamivir(1.2 percent and 1.3 percent, respectively) was lower than thatamong subjects assigned to placebo (4.8 percent; P<0.001and P=0.001 for the comparison with once-daily and twice-dailyoseltamivir, respectively). The protective efficacy of oseltamivirin the two active-treatment groups combined was 74 percent (95percent confidence interval, 53 to 88 percent) at all the sitescombined and 82 percent (95 percent confidence interval, 60to 93 percent) at sites in Virginia, where the rate of influenzainfection was higher than the overall rate. For culture-provedinfluenza, the rate of protective efficacy in the two oseltamivirgroups combined was 87 percent (95 percent confidence interval,65 to 96 percent). The rate of laboratory-confirmed influenzainfection was lower with oseltamivir than with placebo (5.3percent vs. 10.6 percent, P<0.001). Oseltamivir was welltolerated but was associated with a greater frequency of nausea(12.1 percent and 14.6 percent in the once-daily and twice-dailygroups, respectively) and vomiting (2.5 percent and 2.7 percent,respectively) than was placebo (nausea, 7.1 percent; vomiting,0.8 percent). However, the frequency of premature discontinuationof drug or placebo was similar among the three groups (3.1 to4.0 percent).
Conclusions Oseltamivir administered daily for six weeks bythe oral route is safe and effective for the prevention of influenza.
Source Information
From the University of Virginia, Charlottesville (F.G.H.); Baylor College of Medicine, Houston (R.L.A.); Eastern Virginia Medical School, Norfolk (M.S.); Pharmaceutical Research Associates, Lenexa, Kans. (C.J.); Infectious Diseases Physicians, Fairfax, Va. (D. Poretz); University of Texas, Galveston (D. Paar); Roche Global Development, Welwyn, United Kingdom (L.H., P.W.); and Gilead Sciences, Foster City, Calif. (R.G.M.).
Address reprint requests to Dr. Hayden at the Department of Medicine, Box 473, University of Virginia Health Sciences Center, Charlottesville, VA 22908.
Jefferson, T., Jones, M., Doshi, P., Del Mar, C.
(2009). Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis. BMJ
339: b5106-b5106
[Abstract][Full Text]
Khazeni, N., Bravata, D. M., Holty, J.-E. C., Uyeki, T. M., Stave, C. D., Gould, M. K.
(2009). Systematic Review: Safety and Efficacy of Extended-Duration Antiviral Chemoprophylaxis Against Pandemic and Seasonal Influenza. ANN INTERN MED
151: 464-473
[Abstract][Full Text]
Ellis, C., McEwen, R.
(2009). Who should receive Tamiflu for swine flu?. BMJ
339: b2698-b2698
[Full Text]
Kuzuhara, T., Kise, D., Yoshida, H., Horita, T., Murazaki, Y., Nishimura, A., Echigo, N., Utsunomiya, H., Tsuge, H.
(2009). Structural Basis of the Influenza A Virus RNA Polymerase PB2 RNA-binding Domain Containing the Pathogenicity-determinant Lysine 627 Residue. J. Biol. Chem.
284: 6855-6860
[Abstract][Full Text]
Wattanagoon, Y., Stepniewska, K., Lindegardh, N., Pukrittayakamee, S., Silachamroon, U., Piyaphanee, W., Singtoroj, T., Hanpithakpong, W., Davies, G., Tarning, J., Pongtavornpinyo, W., Fukuda, C., Singhasivanon, P., Day, N. P. J., White, N. J.
(2009). Pharmacokinetics of High-Dose Oseltamivir in Healthy Volunteers. Antimicrob. Agents Chemother.
53: 945-952
[Abstract][Full Text]
Bouvier, N. M., Lowen, A. C., Palese, P.
(2008). Oseltamivir-Resistant Influenza A Viruses Are Transmitted Efficiently among Guinea Pigs by Direct Contact but Not by Aerosol. J. Virol.
82: 10052-10058
[Abstract][Full Text]
Carroll, T. D., Matzinger, S. R., Genesca, M., Fritts, L., Colon, R., McChesney, M. B., Miller, C. J.
(2008). Interferon-Induced Expression of MxA in the Respiratory Tract of Rhesus Macaques Is Suppressed by Influenza Virus Replication. J. Immunol.
180: 2385-2395
[Abstract][Full Text]
Schentag, J. J., Hill, G., Chu, T., Rayner, C. R.
(2007). Similarity in Pharmacokinetics of Oseltamivir and Oseltamivir Carboxylate in Japanese and Caucasian Subjects. J Clin Pharmacol
47: 689-696
[Abstract][Full Text]
Thomas, J. K., Noppenberger, J.
(2007). Avian influenza: A review. Am J Health Syst Pharm
64: 149-165
[Abstract][Full Text]
Abe, M., Smith, J., Urae, A., Barrett, J., Kinoshita, H., Rayner, C. R
(2006). Pharmacokinetics of Oseltamivir in Young and Very Elderly Subjects. The Annals of Pharmacotherapy
40: 1724-1730
[Abstract][Full Text]
Robson, R., Buttimore, A., Lynn, K., Brewster, M., Ward, P.
(2006). The pharmacokinetics and tolerability of oseltamivir suspension in patients on haemodialysis and continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant
21: 2556-2562
[Abstract][Full Text]
Woodhead, M., Blasi, F., Ewig, S., Huchon, G., Leven, M., Ortqvist, A., Schaberg, T., Torres, A., van der Heijden, G., Verheij, T. J. M.
(2005). Guidelines for the management of adult lower respiratory tract infections. Eur Respir J
26: 1138-1180
[Abstract][Full Text]
Turner, R. B.
(2005). Studies of "natural" remedies for the common cold: pitfalls and pratfalls. CMAJ
173: 1051-1052
[Full Text]
Moscona, A.
(2005). Neuraminidase inhibitors for influenza.. NEJM
353: 1363-1373
[Full Text]
(2005). Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia. Am. J. Respir. Crit. Care Med.
171: 388-416
[Full Text]
Langley, J. M., Faughnan, M. E.
(2004). Prevention of influenza in the general population. CMAJ
171: 1213-1222
[Abstract][Full Text]
Oxford, J., Balasingam, S., Lambkin, R.
(2004). A new millennium conundrum: how to use a powerful class of influenza anti-neuraminidase drugs (NAIs) in the community. J Antimicrob Chemother
53: 133-136
[Abstract][Full Text]
Rothberg, M. B., Bellantonio, S., Rose, D. N.
(2003). Management of Influenza in Adults Older than 65 Years of Age: Cost-Effectiveness of Rapid Testing and Antiviral Therapy. ANN INTERN MED
139: 321-329
[Abstract][Full Text]
Dunn, J. J., Gordon, C., Kelley, C., Carroll, K. C.
(2003). Comparison of the Denka-Seiken INFLU A{middle dot}B-Quick and BD Directigen Flu A+B Kits with Direct Fluorescent-Antibody Staining and Shell Vial Culture Methods for Rapid Detection of Influenza Viruses. J. Clin. Microbiol.
41: 2180-2183
[Abstract][Full Text]
Oliveira, E. C., Lee, B., Colice, G. L.
(2003). Influenza in the Intensive Care Unit. J Intensive Care Med
18: 80-91
[Abstract]
Horcajada, J.P., Pumarola, T., Martinez, J.A., Tapias, G., Bayas, J.M., de la Prada, M., Garcia, F., Codina, C., Gatell, J.M., Jimenez de Anta, M.T.
(2003). A nosocomial outbreak of influenza during a period without influenza epidemic activity. Eur Respir J
21: 303-307
[Abstract][Full Text]
Stiver, G.
(2003). The treatment of influenza with antiviral drugs. CMAJ
168: 49-57
[Abstract][Full Text]
(2002). {blacktriangledown}Oseltamivir for influenza. DTB
40: 89-91
[Abstract][Full Text]
Wang, M. Z., Tai, C. Y., Mendel, D. B.
(2002). Mechanism by Which Mutations at His274 Alter Sensitivity of Influenza A Virus N1 Neuraminidase to Oseltamivir Carboxylate and Zanamivir. Antimicrob. Agents Chemother.
46: 3809-3816
[Abstract][Full Text]
Reina, J., Padilla, E., Alonso, F., Ruiz de Gopegui, E., Munar, M., Mari, M.
(2002). Evaluation of a New Dot Blot Enzyme Immunoassay (Directigen Flu A+B) for Simultaneous and Differential Detection of Influenza A and B Virus Antigens from Respiratory Samples. J. Clin. Microbiol.
40: 3515-3517
[Abstract][Full Text]
Lee, P. Y., Matchar, D. B., Clements, D. A., Huber, J., Hamilton, J. D., Peterson, E. D.
(2002). Economic Analysis of Influenza Vaccination and Antiviral Treatment for Healthy Working Adults. ANN INTERN MED
137: 225-231
[Abstract][Full Text]
Stephenson, I., Nicholson, K.G.
(2001). Influenza: vaccination and treatment. Eur Respir J
17: 1282-1293
[Abstract][Full Text]
Oliveira, E. C., Marik, P. E., Colice, G.
(2001). Influenza Pneumonia : A Descriptive Study. Chest
119: 1717-1723
[Abstract][Full Text]
Niederman, M. S., Mandell, L. A., Anzueto, A., Bass, J. B., Broughton, W. A., Campbell, G. D., Dean, N., File, T., Fine, M. J., Gross, P. A., Martinez, F., Marrie, T. J., Plouffe, J. F., Ramirez, J., Sarosi, G. A., Torres, A., Wilson, R., Yu, V. L.
(2001). Guidelines for the Management of Adults with Community-acquired Pneumonia . Diagnosis, Assessment of Severity, Antimicrobial Therapy, and Prevention. Am. J. Respir. Crit. Care Med.
163: 1730-1754
[Full Text]
Bantia, S., Parker, C. D., Ananth, S. L., Horn, L. L., Andries, K., Chand, P., Kotian, P. L., Dehghani, A., El-Kattan, Y., Lin, T., Hutchison, T. L., Montgomery, J. A., Kellog, D. L., Babu, Y. S.
(2001). Comparison of the Anti-Influenza Virus Activity of RWJ-270201 with Those of Oseltamivir and Zanamivir. Antimicrob. Agents Chemother.
45: 1162-1167
[Abstract][Full Text]
Nichol, K. L.
(2001). Cost-Benefit Analysis of a Strategy to Vaccinate Healthy Working Adults Against Influenza. Arch Intern Med
161: 749-759
[Abstract][Full Text]
Sidwell, R. W., Smee, D. F., Huffman, J. H., Barnard, D. L., Bailey, K. W., Morrey, J. D., Babu, Y. S.
(2001). In Vivo Influenza Virus-Inhibitory Effects of the Cyclopentane Neuraminidase Inhibitor RWJ-270201. Antimicrob. Agents Chemother.
45: 749-757
[Abstract][Full Text]
Welliver, R., Monto, A. S., Carewicz, O., Schatteman, E., Hassman, M., Hedrick, J., Jackson, H. C., Huson, L., Ward, P., Oxford, J. S., for the Oseltamivir Post Exposure Prophylaxis Inve,
(2001). Effectiveness of Oseltamivir in Preventing Influenza in Household Contacts: A Randomized Controlled Trial. JAMA
285: 748-754
[Abstract][Full Text]
van Elden, L. J. R., Nijhuis, M., Schipper, P., Schuurman, R., van Loon, A. M.
(2001). Simultaneous Detection of Influenza Viruses A and B Using Real-Time Quantitative PCR. J. Clin. Microbiol.
39: 196-200
[Abstract][Full Text]
Gonzales, R., Sande, M. A.
(2000). Uncomplicated Acute Bronchitis. ANN INTERN MED
133: 981-991
[Abstract][Full Text]
Couch, R. B.
(2000). Influenza: Prospects for Control. ANN INTERN MED
133: 992-998
[Abstract][Full Text]
Couch, R. B.
(2000). Prevention and Treatment of Influenza. NEJM
343: 1778-1787
[Full Text]
Cifu, A., Levinson, W.
(2000). Influenza. JAMA
284: 2847-2849
[Full Text]
Wright, P.
(2000). Influenza in the Family. NEJM
343: 1331-1332
[Full Text]
Monto, A. S.
(2000). Preventing Influenza in Healthy Adults: The Evolving Story. JAMA
284: 1699-1701
[Full Text]
KASISKE, B. L., VAZQUEZ, M. A., HARMON, W. E., BROWN, R. S., DANOVITCH, G. M., GASTON, R. S., ROTH, D., SCANDLING, J. D. JR., SINGER, G. G.
(2000). Recommendations for the Outpatient Surveillance of Renal Transplant Recipients. J. Am. Soc. Nephrol.
11
: S1-S86
[Abstract][Full Text]
Nichol, K. L
(2000). Oseltamivir once or twice daily safely prevented influenza. Evid. Based Med.
5: 81-81
[Full Text]
Weir, E.
(2000). Coping with flu season. CMAJ
162: 861-861
[Full Text]
Treanor, J. J., Hayden, F. G., Vrooman, P. S., Barbarash, R., Bettis, R., Riff, D., Singh, S., Kinnersley, N., Ward, P., Mills, R. G., for the US Oral Neuraminidase Study Group,
(2000). Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute Influenza: A Randomized Controlled Trial. JAMA
283: 1016-1024
[Abstract][Full Text]
(1999). Oseltamivir -- A Second Neuraminidase Inhibitor for Influenza. JWatch Infect. Diseases
1999: 1-1
[Full Text]
(1999). An Oral Neuraminidase Inhibitor to Prevent and Treat Influenza. JWatch General
1999: 5-5
[Full Text]
Cox, N. J., Hughes, J. M.
(1999). New Options for the Prevention of Influenza. NEJM
341: 1387-1388
[Full Text]
Previous
